Clinical trials: Acute Phase
Induction Chemotherapy, Acute T-Lymphocytic Leukemia
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients
The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.
- Conditions
- Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia, T-cell/Myeloid Mixed Phenotype Acute Leukemia
- Trial name
- NCT04446130
- Testing
- Decitabine combined with HAAG Regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
This is a clinical research study for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The study will test a new treatment called "autologous nano CD5-CAR T cells".
- Conditions
- T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma, Relapsed/Refractory Hematologic Malignancies
- Trial name
- NCT07678307
- Testing
- Autologous nano CD5-CAR T Cells
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML, Adult
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.
This is a non-randomized prospective open-label single-arm clinical phase I trial investigating dose finding, feasibility and safety of the combined treatment of HDM201 and midostaurin in patients with relapsed/refractory acute…
- Trial name
- HDMM (NCT04496999)
- Testing
- HDM201, Midostaurin
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Coronary Syndrome
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Cardiovascular disease remains the most pressing healthcare issue for developed countries and is becoming so for developing countries. There are a number of chronic therapies available for long-term management of risk.
- Trial name
- CHI SQUARE (NCT01201837)
- Testing
- CER-001
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 507 people
- Sponsor
- Cerenis Therapeutics, SA
Acute Myeloid Leukemia
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
The purpose of the phase 1b/2 study is to determine whether Onvansertib given orally daily for 5 consecutive days every 28 days is safe and tolerable in adult patients who have relapsed/refractory Acute Myeloid Leukemia (AML), or…
- Trial name
- NCT03303339
- Testing
- Onvansertib, Cytarabine, Decitabine
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cardiff Oncology
Acute-On-Chronic Liver Failure, Alcoholic Hepatitis
A-TANGO Phase 2 Study
The purpose of this research is to know if a new combination of drugs (TAK-242 and G-CSF) in combination with standard therapy for acute-on-chronic liver failure (ACLF) is more effective than standard therapy for ACLF treatment…
- Conditions
- Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic
- Trial name
- A-TANGO (NCT06890039)
- Testing
- TAK-242, G-CSF (Filgrastim)
- Where
- United Kingdom
- Volunteers
- 78 people
- Sponsor
- Yaqrit Ltd
Shock, Cardiogenic
A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack
Tilarginine Acetate Injection is a new type of drug that temporarily stops the body from making a bodily substance called nitric oxide. The body may produce excess nitric oxide following severe heart damage leading to shock.
- Trial name
- NCT00112281
- Testing
- Tilarginine Acetate Injection intravenous infusion
- Where
- 102 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- Arginox Pharmaceuticals
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine…
- Trial name
- NCT01861002
- Testing
- Azacytidine, Fludarabine, Cytarabine
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS.
- Trial name
- AML (NCT02576301)
- Testing
- Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Mateon Therapeutics
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This study is a global multicenter randomized factorial double-blind, placebo-controlled trial designed to evaluate (i) efficacy and safety of nitazoxanide 600 mg administered orally twice daily for five days compared to a…
- Trial name
- NCT01610245
- Testing
- Nitazoxanide, Oseltamivir
- Where
- 167 sites in United States, Australia and 3 more
- Volunteers
- 1,941 people
- Sponsor
- Romark Laboratories L.C.
Ischemic Heart Disease, Myocardial Infarction
Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT to Predict Left Ventricular Remodelling in Patients Reperfused in the Acute Phase of MI
Left myocardial infarction (MI), has a negative impact of long term morbidity and mortality. Even in patients treated successfully by angioplasty in the acute phase of infarct, the remodelling is observed in approximately 30% of…
- Trial name
- NCT00487812
- Testing
- Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acute GVHD
Prebiotic Galacto-oligosaccharide and Acute GVHD
The purpose of this study is to determine whether the carbohydrate prebiotic (dietary supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria in the gut) and help prevent graft-versus host…
- Trial name
- NCT04373057
- Testing
- Galacto-oligosaccharide, Maltodextrin
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- University of Kansas Medical Center
COVID-19 Pneumonia, Acute Lung Injury
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
The study is a prospective, randomized, placebo-controlled, double-blind phase 2 clinical study of the efficacy and safety of CERC-002, a potent inhibitor of LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes…
- Conditions
- COVID-19 Pneumonia, Acute Lung Injury, ARDS
- Trial name
- NCT04412057
- Testing
- CERC-002
- Where
- 11 sites in United States
- Volunteers
- 88 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Acute Myocardial Infarction, Heart Failure
Safety and Efficacy on Cell-based Therapy in Patients With Recent Large Acute Myocardial Infarction
The purpose of this study is to test bone marrow mononuclear cells for patients with recent heart attack who are at high risk of experiencing heart failure. This study drug is made of you own cells.
- Trial name
- ReNeW (NCT00691834)
- Testing
- Intracoronary delivery of unfractionated bone marrow mononuclear cells
- Sponsor
- Duke University
Acute Myeloid Leukemia
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A study is designed to assess if BL-8040 in combination with cytarabine (Ara-C) can help controlling the disease in patients with Acute Myeloid Leukemia (AML) that have relapsed or did not respond adequately to previous…
- Trial name
- NCT01838395
- Testing
- Ara-C, BL-8040
- Where
- 10 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- BioLineRx, Ltd.
Acute Promyelocytic Leukemia
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
SY-2101 is being studied as a treatment for participants with a type of leukemia called acute promyelocytic leukemia (APL). SY-2101 is an oral formulation of a drug called arsenic trioxide (ATO).
- Trial name
- NCT04996030
- Testing
- SY-2101, Arsenic Trioxide
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Syros Pharmaceuticals
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
- Trial name
- NCT05677893
- Testing
- MBS-COV
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
Acute Myeloid Leukemia
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
This clinical research study is being done to answer questions about how to treat cancer. To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons.
- Trial name
- NCT06626633
- Testing
- CRD3874
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
Abdominal Aortic Aneurysm
ARBITER-II: Aorfix™ Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels
To assess the safety and performance of Aorfix™ Stent Grafts in the treatment of Abdominal Aortic and Aorto-Iliac Aneurysm where a significant degree of vessel angulation exists at the neck of the aneurysm or in the common iliac…
- Trial name
- ARBITER-II (NCT00442065)
- Testing
- Aorfix™ Stent Grafts (AAA endovascular procedure)
- Where
- 6 sites in Czechia, Germany and 3 more
- Volunteers
- 30 people
- Sponsor
- Lombard Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.